Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases

Abstract

Background: Hypertension is a global health epidemic, and blood uric acid levels are a major risk factor for the development of cardiovascular and renal problems. Serum uric acid levels may be reduced as a result of treatment, which may reduce cardiovascular risk factors. Losartan has a pleiotropic uricosuric effect that lowers the risk of future cardiovascular problems. Aims and Objectives: To study and evaluate how losartan affected serum uric acid levels in people with essential hypertension. Materials and Methods: A source of 120 newly diagnosed participants with stage 1 and stage 2 essential hypertension aged between 31 and 65 years, both genders, with elevated serum uric acid levels, were recruited. Tablet Losartan 50 mg once daily during the morning session for 1 month. The changes in the serum uric acid levels and blood pressure at baseline, 1 month, 3 months, and 6 months were measured and analyzed. Results: Stage-2 hypertension (53.3%) was common, followed by stage-3 (37.5%) and stage-1 hypertension (9.17%). The mean levels and mean reduction of systolic blood pressure, diastolic blood pressure, and serum uric acid levels were statistically significant (P < 0.05). Adverse drug reactions such as headache were observed in 2.5% of cases, dizziness in 1.67%, and mild hypotension in 0.83% of cases. Conclusion: Losartan therapy for 6 months can effectively decrease the serum uric acid and blood pressure in patients with essential hypertension.